Literature DB >> 7649217

Cathepsin D from Alzheimer's-diseased and normal brains.

R E Kohnken1, U S Ladror, G T Wang, T F Holzman, B E Miller, G A Krafft.   

Abstract

An acid protease activity from human brain was found to cleave a fluorogenic peptide substrate encompassing the amino terminus of Alzheimer's amyloid-beta peptide (A beta). The protease was isolated and determined to be cathepsin D based on chromatographic, immunological, and enzymatic data. Analysis of the cleavage sites indicated that cathepsin D hydrolyzed the methionine--aspartate bond generating the in vivo amino terminus of A beta. These data suggested that cathepsin D could be involved in amyloidogenic processing of the amyloid precursor protein. Consequently, cathepsin D from both Alzheimer's-diseased and control brains was compared to determine whether there were any differences which could account for an increase in A beta production in Alzheimer's disease. No differences were detected in isoform composition or tissue content of cathepsin D as measured by 2-D IEF-SDS-PAGE. Enzymological characterization of brain cathepsin D demonstrated that it could undergo a previously undescribed pH-dependent reversible activation. However, that activation appeared identical for both AD and normal brain enzymes. These data demonstrate that concentration, isoform distribution, and several enzymological characteristics of cathepsin D are not distinguishable between AD and normal brain. The pH dependence of cathepsin D activity suggests, however, that its intracellular localization may be important in considering the potential role of cathepsin D in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649217     DOI: 10.1006/exnr.1995.1013

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  4 in total

1.  Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics.

Authors:  Christopher D Aluise; Renã A Sowell Robinson; Tina L Beckett; M Paul Murphy; Jian Cai; William M Pierce; William R Markesbery; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2010-04-23       Impact factor: 5.996

Review 2.  Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications.

Authors:  Gaetano Leto; Francesca M Tumminello; Marilena Crescimanno; Carla Flandina; Nicola Gebbia
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

3.  Association of Retromer Deficiency and Tau Pathology in Down Syndrome.

Authors:  Mary Elizabeth Curtis; Tiffany Smith; Daohai Yu; Domenico Praticò
Journal:  Ann Neurol       Date:  2022-02-25       Impact factor: 11.274

4.  Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration.

Authors:  Yuek Ling Chai; Joyce R Chong; Jiaju Weng; David Howlett; Andrea Halsey; Jasinda H Lee; Johannes Attems; Dag Aarsland; Paul T Francis; Christopher P Chen; Mitchell K P Lai
Journal:  Brain Pathol       Date:  2018-10-17       Impact factor: 6.508

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.